INFORMATION DISCLOSUR	Ε
STATEMENT BY APPLICAN	т
(Not for submission under 37 CFR 1.99	1)

	Application Number		10698179
	Filing Date		2003-10-30
	First Named Inventor Thom		as W. Kenny
	Art Unit		3784
	Examiner Name	Ford,	John K.
	Attorney Docket Number		COOL-01302

				U.S.	Remove	
Examiner Initial*	Cite No	Patent Number	atent Number Kind Code1 Issue Date		Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	2087521		1937-07-20	A. Mazzola	
	2	2956642		1960-10-18	A. Chaplin et al.	
	3	3220254		1965-11-30	C.R. Halbech	
	4	4021867		1977-05-10	Maxwell, Jr.	
	5	4037889		1977-07-26	Piatt	
	6	4262975		1981-04-21	Heshmat et al.	
	7	4395947		1983-08-02	Despot	
	8	4687167		1987-08-18	Skalka et al.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

5887557

Application Number		10698179
Filing Date		2003-10-30
First Named Inventor Thorn		as W. Kenny
Art Unit		3784
Examiner Name Ford,		John K.
Attorney Docket Number		COOI -01302

Add

Remove

		- 1									
If you wis	h to a	dd a	dditional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add	
				U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove	
Examiner Initial*			Kind Code ¹			Name of Pate of cited Docu	entee or Applicant iment	Rele	es,Columns,Lines where vant Passages or Relev res Appear		
	1		20090159241	A1	2009-0€	i-25	Lipp et al.				
	2		20090183520	A1	2009-07	-23	Yukimoto				
	3		20090225513	A1	2009-09	i-10	Correa et al.				
	4		20090262495	A1	2009-10	1-22	Neudorfer				
	5		20100132640	A1	2010-06	i-03	Methley et al.				
If you wis	h to a	dd a	dditional U.S. Publi	shed Ap	plication	citatio	information p	olease click the Ad	d butte	on. Add	
					FOREIG	ON PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No		reign Document umber ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т
	1										

NON-PATENT LITERATURE DOCUMENTS

If you wish to add additional Foreign Patent Document citation information please click the Add button

1999-03-30 Battlogg

Examiner Initials*	xaminer Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title (book, magazine, journal, serial, symposisum, catalog, etc), date, pages(s), volume-issue numl publisher, city and/or country where published.				
	1				

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTIO Patent Documents at year-USPTIO_GOV or MEPE 901.6.2 Elector office that issued the document, by the holietier code (WIPO Standard ST.3). 3 For dystagenee platent bocuments, by the indication of the year of the Propriet many percectible seed number of the Pederal concurrent, and focus on the second of the proprieties are not provided to the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if Expolite Impropriet intention in estation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10698179	
Filing Date			2003-10-30	
	First Named Inventor	Thom	as W. Kenny	
	Art Unit		3784	
	Examiner Name	Ford,	John K.	
	Attorney Docket Number		COOL-01302	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/Thomas B. Haverstock/	Date (YYYY-MM-DD)	2012-06-15
Name/Print	Thomas R Haverstock	Registration Number	32571

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, ourspant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 11, 4, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by whiter a published application, an application open to public inscredience or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.